BC Innovations | Nov 13, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Mouse studies suggest inhibiting MCP-1 or its receptor CCR2 could help treat arthritis. In a mouse model of anti-collagen antibody-induced arthritis, systemic MCP-1 knockout or a neutralizing antibody against CCR2 decreased disease severity...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinal detachment Mouse studies suggest inhibiting TRPV4 or its downstream mediator MCP-1 could help treat retinal detachment. In a mouse model of retinal detachment, systemic or Müller glia- and astrocyte-specific TRPV4 knockout, a tool...
BC Innovations | Sep 10, 2018
Distillery Therapeutics

Neurology

INDICATION: Encephalopathy Patient sample and mouse studies suggest inhibiting the JAK/STAT1 pathway, the interaction between MCP-1 and CCR2, or phagocyte activation could help treat Rasmussen encephalitis. In postmortem brain samples from patients, levels of phosphorylated...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago....
BC Innovations | May 11, 2018
Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
BC Innovations | Nov 15, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinopathy of prematurity Patient sample and mouse studies suggest inhibiting mast cell degranulation, TPSB2 or MCP-1-CCR2 signaling could help treat retinopathy of prematurity (ROP). In plasma samples from preterm neonatal infants who developed ROP,...
BC Extra | Oct 9, 2017
Company News

Management tracks: BMS, Amicus, Armo, Noxxon

Bristol-Myers Squibb Co. (NYSE:BMY) named Saurabh Saha SVP and global head of translational medicine. He was a venture partner at Atlas Venture , as well as president and CEO at Delinia Inc. , which Celgene Corp. (NASDAQ:CELG)...
BC Week In Review | Jul 14, 2017
Clinical News

Noxxon starts Phase I/II of olaptesed pegol, Keytruda combo in cancer

Noxxon Pharma N.V. (Euronext:ALNOX) began a 2-part Phase I/II trial to evaluate olaptesed pegol (NOX-A12) plus Keytruda pembrolizumab in about 10 patients with metastatic colorectal cancer and 10 patients with metastatic pancreatic cancer. Patients will...
BC Innovations | Jun 8, 2017
Targets & Mechanisms

Pumping iron

A natural compound from the Japanese Hinoki tree may hold the answer to iron transport diseases treated inadequately by phlebotomy, chelation therapy or dietary supplements. In Science last month, a University of Illinois -led group...
BC Innovations | May 31, 2017
Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary Patient sample and mouse studies suggest inhibiting KRAS or MCP-1 could help treat malignant pleural effusions in KRAS-mutant cancers. In non-small cell lung cancer (NSCLC) patients, KRAS mutations in metastatic tumors were associated...
Items per page:
1 - 10 of 108
BC Innovations | Nov 13, 2018
Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Mouse studies suggest inhibiting MCP-1 or its receptor CCR2 could help treat arthritis. In a mouse model of anti-collagen antibody-induced arthritis, systemic MCP-1 knockout or a neutralizing antibody against CCR2 decreased disease severity...
BC Innovations | Oct 11, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinal detachment Mouse studies suggest inhibiting TRPV4 or its downstream mediator MCP-1 could help treat retinal detachment. In a mouse model of retinal detachment, systemic or Müller glia- and astrocyte-specific TRPV4 knockout, a tool...
BC Innovations | Sep 10, 2018
Distillery Therapeutics

Neurology

INDICATION: Encephalopathy Patient sample and mouse studies suggest inhibiting the JAK/STAT1 pathway, the interaction between MCP-1 and CCR2, or phagocyte activation could help treat Rasmussen encephalitis. In postmortem brain samples from patients, levels of phosphorylated...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

Kinase inhibitor company Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) and cancer assay developer Genomic Health Inc. (NASDAQ:GHDX) each hit all-time highs in the wake of data readouts at the American Society of Clinical Oncology meeting in Chicago....
BC Innovations | May 11, 2018
Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
BC Innovations | Nov 15, 2017
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinopathy of prematurity Patient sample and mouse studies suggest inhibiting mast cell degranulation, TPSB2 or MCP-1-CCR2 signaling could help treat retinopathy of prematurity (ROP). In plasma samples from preterm neonatal infants who developed ROP,...
BC Extra | Oct 9, 2017
Company News

Management tracks: BMS, Amicus, Armo, Noxxon

Bristol-Myers Squibb Co. (NYSE:BMY) named Saurabh Saha SVP and global head of translational medicine. He was a venture partner at Atlas Venture , as well as president and CEO at Delinia Inc. , which Celgene Corp. (NASDAQ:CELG)...
BC Week In Review | Jul 14, 2017
Clinical News

Noxxon starts Phase I/II of olaptesed pegol, Keytruda combo in cancer

Noxxon Pharma N.V. (Euronext:ALNOX) began a 2-part Phase I/II trial to evaluate olaptesed pegol (NOX-A12) plus Keytruda pembrolizumab in about 10 patients with metastatic colorectal cancer and 10 patients with metastatic pancreatic cancer. Patients will...
BC Innovations | Jun 8, 2017
Targets & Mechanisms

Pumping iron

A natural compound from the Japanese Hinoki tree may hold the answer to iron transport diseases treated inadequately by phlebotomy, chelation therapy or dietary supplements. In Science last month, a University of Illinois -led group...
BC Innovations | May 31, 2017
Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary Patient sample and mouse studies suggest inhibiting KRAS or MCP-1 could help treat malignant pleural effusions in KRAS-mutant cancers. In non-small cell lung cancer (NSCLC) patients, KRAS mutations in metastatic tumors were associated...
Items per page:
1 - 10 of 108